It is now well accepted that IL-36 cytokines are paramount in psoriasis pathogenesis, and IL-36 receptor inhibition represents a promising therapeutic strategy for treating generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP). This evidence concerns the gene IL1RL2 and psoriasis.